Many benzodiazepines of the type whose receptors are found in peripheral tissues cause the differentiation of cultured Friend erythroleukemia cells. The maximal level of induction of hemoglobin synthesis is 10-80% of the cells, depending on the compound tested. The Induction is concentration and time dependent, requiring micromolar amounts of the drugs and about 5 days of treatment for full expression. The time course is very similar to that observed for a well-studied inducer, dimethyl sulfbxide. The affinities of the agents for the peripheral-type benzodiazepine binding site are not correlated with their capacity to induce differentiation. Also, the biological effect is stereospecific since the (3S) btereoisomer Roll-6896 is at least an order of magnitude more potent than its (3R) enantiomer, Rol1-6893. The benzodiazepine effect exhibits definite structure-activity relationships. A 1-methyl group is an absolute requirement, although this is not sufficient in itself Hydroxyl and methoxyl groups at the 4' position enhance the biological activity, but 4'-chloro decreases it. Substitutions at the 2', 6', and 4 positions also decrease the biological activity, as does the lack of a 2-carbonyl group. These data suggest that the benzodiazepines act in a specific manner to induce the differentiation of Friend erythroleukemia cells.
The binding sites for the benzodiazepines (BZDs) are divided into two major groups-"central-type" and "peripheraltype"-on the basis of their tissue localization (1) . The central-type receptors, found only in brain, are thought to be involved in the therapeutic actions of these compounds and have been intensively studied (for review see ref.
2). Although the peripheral-type sites are found widely distributed in many tissues and cells (3) (4) (5) (6) (7) (8) (9) (10) , and the structural requirements for binding have been defined (11) , the role of these sites in vivo is unknown. However, a number of in vitro studies have demonstrated that the BZDs have diverse noncentral biological effects (12) (13) (14) (15) (16) (17) (18) . In particular, Matthew et al. (19) found that certain BZDs accelerated the onset of spontaneous melanogenesis in mouse B16/C3 melanoma cells, and Clarke and Ryan (20) observed that some BZDs blocked mnitogenesis in Swiss 3T3 cells and induced the differentiation of Friend erythroleukemia (FEL) cells. Most of these studies, however, used very few compounds or did not present any binding characterization, hence no conclusions could be drawn regarding (i) correlations between biological activity and the peripheral-type binding, and (ii) structure-activity relationships. We have reported that in a thymoma cell line, BW5147, the BZDs are anti-proliferative agents whose potencies are correlated with their affinities for the peripheraltype BZD binding site (21) . In this study we extend the observations of Clarke (21) . Detailed characterization of the binding, including its structural requirements, has previously been reported (11) .
The differentiation of DS19 FEL cells was assayed by the benzidine staining method (22 (Table  1 ). The 1-methyl group, required for peripheral-type binding (11) , was likewise essential for the biological effect. However, other structural features were also important for the induction of differentiation, since many 1-methyl-substituted compounds were inactive. It should be noted that whereas modification of the 1-methyl to an ethyl or propenyl eliminated the biological effect, the BZD binding was in contrast enhanced (compare Ro5-6945 and Ro5-6993 to RoS-4864). Similarly halogens at 2', 4', or 6' positions decreased the ability of the compounds to induce differentiation, but the binding affinity was increased by either 2' or 4' substitutions (compare Ro5-4864 and Ro5-3448 to diazepam, and Ro5-5115, Ro5-5122, and Ro5-4608 to Ro5-3464). Halogens at both 2' and 4' positions (RoS-6900) or both 2' and 6' positions (Ro7-5220) resulted in a biologically inactive compound. However, biological potency was enhanced when the 4' substituent was a hydroxyl or methoxyl group (compare (23) , has greater potency. The most potent BZD, Roll-6896, has an ED50 of 9 ,uM, as compared to 100 mM for Me2SO (24, 25) , 2 mM for hexamethylene bisacetamide (HMBA) (22) and 60 ,uM for 6-thioguanine (25) . However, some of these agents, such as HMBA, can induce >95% of the cells. The active BZD compounds tested to date can be grouped into three classes, based upon the maximal percentage of FEL cells inducible for hemoglobin synthesis (see Table 1 ). The significance of these nonoverlapping groups is not clear at 'the present. While the extent of inducibility of each group is dissimilar, the time course of induction is comparable not only for each group but also for that observed with Me2SO.
It has been postulated that the lipophilicity of the BZDs might account for their effect on differentiation (20 Reuben et al. (26) have established the relationship of structure to activity in inducing FEL differentiation among planar-polar compounds related to HMBA. Interestingly, the BZD structure-activity relationship shares a similar characteristic in that the BZDs also possess a hydrophilic polar region in the amide linkage of the 1-nitrogen to the 2-carbonyl. How the other important structural features of the BZDs relate to that of the planar-polar compounds and whether these two classes of inducers act by similar mechanisms is presently unclear. However, the stereospecificity of the BZDs in their biological action has now been demonstrated for the FEL cell system. Such selectivity in the threedimensional configuration of the inducer indicates a specific mechanism of action, the elucidation of which should greatly facilitate our understanding of the phenomena of cell differentiation and malignancy.
